非经典型细胞色素P450氧化还原酶缺陷与月经紊乱及女性不孕密切相关
本研究报道5例19-38岁因月经稀发/闭经和/或不孕就诊的成年女性,经基因检测和类固醇谱分析确诊为非经典型细胞色素P450氧化还原酶缺陷(PORD)。患者表现为孕酮和17-羟孕酮慢性升高、双侧卵巢大囊肿,2例经糖皮质激素抑制后行冻胚移植成功妊娠。提示对孕酮和17-OHP升高合并不孕及卵巢囊肿者应警惕PORD。
要点
- 对不明原因月经紊乱/不孕且孕酮和17-OHP慢性升高者,需考虑非经典型PORD。
- PORD患者常伴双侧卵巢大囊肿,应与非经典型21-羟化酶缺陷鉴别。
- 糖皮质激素抑制孕酮后行IVF冻胚移植,可实现成功妊娠。
核心结论
- 非经典型PORD可在成年女性中以月经紊乱和不孕为首要表现,应纳入鉴别诊断。
研究设计与样本
- 病例系列研究,纳入2015年3月至2018年9月在三个三级内分泌生殖科评估的5例19-38岁女性。
主要发现
- 所有患者均有月经稀发或闭经,无高雄激素表现,血清雌二醇和睾酮偏低至正常,孕酮和17-OHP慢性升高且ACTH刺激后进一步升高。
- 所有患者携带罕见的双等位POR突变,被评为致病或可能致病;盆腔影像显示所有患者双侧卵巢大囊肿。
- 部分患者基础皮质醇低至正常且ACTH反应不足,提示部分性肾上腺功能不全。
- 2例患者经糖皮质激素抑制治疗后行冻胚移植,均获成功妊娠。
关键数值与推荐
- 所有患者孕酮和17-OHP慢性升高,ACTH刺激后17-OHP和21-脱氧皮质醇过度升高,但CYP21A2测序不支持21-OHD。
- 所有患者携带双等位POR突变,按ACMG标准分类为致病或可能致病。
- 所有患者盆腔影像显示双侧卵巢大囊肿。
临床怎么用
- 对不孕女性伴孕酮和17-OHP慢性升高及卵巢大囊肿,应行POR基因检测以诊断PORD。
- 需与非经典型21-羟化酶缺陷鉴别,因PORD涉及多种酶缺陷需特定管理。
- IVF前使用糖皮质激素充分抑制孕酮水平,可行冻胚移植并获成功妊娠。
局限性
- 本文报道的患者数量有限,需在更大样本的非经典型PORD女性中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can cytochrome P450 oxidoreductase deficiency (PORD) be revealed in adult women with menstrual disorders and/or infertility? SUMMARY ANSWER: PORD was biologically and genetically confirmed in five adult women with chronically elevated serum progesterone (P) who were referred for oligo-/amenorrhea and/or infertility. WHAT IS KNOWN ALREADY: PORD is an autosomal recessive disease typically diagnosed in neonates and children with ambiguous genitalia and/or skeletal abnormalities. It is responsible for the decreased activity of several P450 enzymes, including CYP21A2, CYP17A1 and CYP19A1, that are involved in adrenal and/or gonadal steroidogenesis. Little is known about the optimal way to investigate and treat patients with adult-onset PORD. STUDY DESIGN, SIZE, DURATION: In this series, we report five adult females who were evaluated in three tertiary endocrine reproductive departments between March 2015 and September 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: Five women aged 19-38 years were referred for unexplained oligo-/amenorrhea and/or infertility. Genetic testing excluded 21-hydroxylase deficiency (21OH-D), initially suspected due to the increased 17-hydroxyprogesterone (17-OHP) levels. Extensive phenotyping, steroid profiling by mass spectrometry, pelvic imaging and next-generation sequencing of 84 genes involved in gonadal and adrenal disorders were performed in all patients. IVF followed by frozen embryo transfer (ET) under glucocorticoid suppression therapy was performed for two patients. MAIN RESULTS AND THE ROLE OF CHANCE: All patients had oligomenorrhea or amenorrhea. None had hyperandrogenism. Low-normal serum estradiol (E2) and testosterone levels contrasted with chronically increased serum P and 17-OHP levels, which further increased after adrenocorticotrophic hormone (ACTH) administration. Despite excessive P, 17OH-P and 21-deoxycortisol rise after ACTH stimulation suggesting non-classic 21OH-D, CYP21A2 sequencing did not support this hypothesis. Basal serum cortisol levels were low to normal, with inadequate response to ACTH in some women, suggesting partial adrenal insufficiency. All patients harbored rare biallelic POR mutations classified as pathogenic or likely pathogenic according to the American College of Medical Genetics and Genomics standards. Pelvic imaging revealed bilateral ovarian macrocysts in all women. IVF was performed for two women after retrieval of a normal oocyte number despite very low E2 levels during ovarian stimulation. Frozen ET under glucocorticoid suppression therapy led to successful pregnancies. LIMITATIONS, REASONS FOR CAUTION: The number of patients described here is limited and these data need to be confirmed on a larger number of women with non-classic PORD. WIDER IMPLICATIONS OF THE FINDINGS: The diagnosis of PORD must be considered in infertile women with chronically elevated P and 17OH-P levels and ovarian macrocysts. Differentiation of this entity from non-classic 21OH-D is important, as the multiple enzyme deficiency requires a specific management. Successful fertility induction is possible by IVF, providing that P levels be sufficiently suppressed by glucocorticoid therapy prior to implantation. STUDY FUNDING/COMPETING INTEREST(S): No specific funding was used for this study. There are no potential conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Papadakis GE, Dumont A, Bouligand J, et al. Non-classic cytochrome P450 oxidoreductase deficiency strongly linked with menstrual cycle disorders and female infertility as primary manifestations. Hum Reprod. 2020. PMID: 32242900. doi:10.1093/humrep/deaa020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。